Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy
Mené sur 344 patients atteints d'un cancer de la vessie avec envahissement musculaire et inéligibles à une chimiothérapie par cisplatine (durée médiane de suivi : 25,6 mois), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans événement, et la toxicité d'un traitement périopératoire combinant enfortumab védotin et pembrolizumab
Although bladder preservation with trimodal therapy is a category 1 recommendation in the National Comprehensive Cancer Network (NCCN) guidelines for appropriately selected patients with muscle-invasive bladder cancer, the real-world adoption of this type of therapy in the United States remains disappointingly low. Contemporary data suggest that only half the patients (approximately 52%) with muscle-invasive bladder cancer receive any definitive therapy, either trimodal therapy or radical cystectomy, and the majority ultimately undergo surgery. The limited use of bladder-sparing approaches probably reflects several factors, including a lack of head-to-head comparative data, institutional or physician preference for surgery, and challenges in accurately selecting . . .
New England Journal of Medicine , éditorial, 2026